Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Safety Monitoring Could Rely On Data Links, Menactra Model – McClellan

Executive Summary

Former FDA Commissioner Mark McClellan was one of the main drivers behind the language in the FDA Amendments Act mandating an active surveillance system, and he continues to be involved in shaping the program how will be implemented

You may also be interested in...



FDA’s Sentinel Framework Should Preclude “Unbridled” Data Mining – Platt

FDA's nascent electronic post-market drug safety monitoring project - Sentinel - should be designed to investigate only known problems or specific issues raised by spontaneous reports or studies, Harvard University's Richard Platt recommends

FDA’s Sentinel Framework Should Preclude “Unbridled” Data Mining – Platt

FDA's nascent electronic post-market drug safety monitoring project - Sentinel - should be designed to investigate only known problems or specific issues raised by spontaneous reports or studies, Harvard University's Richard Platt recommends

FDA’s Sentinel Program Readies For Patrol As Stakeholders Watch For Details

HHS unveiled the first phase of FDA's "Sentinel" post-market drug safety surveillance initiative with fanfare May 22, but stakeholders will have to wait a while for details on funding and the timing of a full-scale rollout

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049611

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel